IMCR — Immunocore Holdings plc
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1671927 ·
Last close
$29.41
Market Cap
$1.50B
52W High
$33.86
52W Low
$27.56
ADV30
350,333
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 106,677,000 | 106,243,000 | 7,280,000 | 12,971,000 | 1,072,095,000 | 452,675,000 | 678,422,000 |
| Dec 2025 | 104,478,000 | 101,775,000 | -19,691,000 | -30,060,000 | 1,067,269,000 | 467,709,000 | 686,236,000 |
| Sep 2025 | 103,693,000 | 103,180,000 | -7,171,000 | -177,000 | 1,102,500,000 | 498,413,000 | 705,936,000 |
| Jun 2025 | 97,964,000 | 96,924,000 | -14,875,000 | -10,300,000 | 1,082,387,000 | 487,933,000 | 693,906,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,712,000
Investing CF
$-16,340,000
Financing CF
$12,371,000
CapEx
$-4,340,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.70
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-831,275,000
Inventory
$6,742,000
Receivables
$101,121,000
ST Investments
$396,444,000
EBIT TTM
$-6,425,000
Pretax Income TTM
$-19,100,000
Interest Exp TTM
$12,675,000
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$412,812,000
EBITDA
$-11,369,000
Free Cash Flow
$58,577,376
Enterprise Value
$1,057,241,472
Total Cash
$844,896,000
Total Debt
$435,683,008
Shares Out
50,865,574
Trailing EPS
$-0.56
Book Value
$7.52
ROE
-7.1%
ROA
-0.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 400,016,000 | -45,353,000 | -35,514,000 | 1,067,269,000 | 686,236,000 | — | -10,712,000 |
| Dec 2024 | 310,202,000 | -70,461,000 | -51,087,000 | 1,009,506,000 | 648,790,000 | — | 26,061,000 |
| Dec 2023 | 249,428,000 | -59,649,000 | -55,287,000 | 597,001,000 | 228,158,000 | — | 2,940,000 |
| Dec 2022 | 174,361,000 | -51,708,000 | -52,543,000 | 526,762,000 | 187,859,000 | — | -49,209,000 |
TTM Snapshot
Revenues TTM
$145,098,000
NetIncome TTM
$9,642,000
OpCashFlow TTM
$0
Assets (Latest)
$1,009,506,000
Forward EPS
$-0.67
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMTX | Immatics N.V. | $1.53B | $11.19 | — |
| MAZE | Maze Therapeutics, Inc. | $1.46B | $26.35 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.56B | $2.97 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.57B | $106.85 | — |
| VIR | Vir Biotechnology, Inc. | $1.58B | $9.38 | — |
News headlines (Yahoo Finance, 1h cache)
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe
2026-05-25 15:08 · Yahoo
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
2026-05-25 14:53 · Yahoo
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
2026-05-22 16:14 · Yahoo
Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet
2026-05-22 13:55 · Yahoo
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
2026-05-21 15:31 · Yahoo
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
2026-05-21 14:37 · Yahoo
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
2026-05-21 13:19 · Yahoo
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
2026-05-20 14:51 · Yahoo
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know
2026-05-20 14:45 · Yahoo
FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer Therapy
2026-05-20 13:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.